Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 5/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065370 | 0.89 | MEN1 (0.38) | RBP4BACE1CHRM4CHRM3USP30 | |
| SCHEMBL5724086 | 0.89 | RBP4 (0.36) | RBP4BACE1RORCCHRM4CHRM3 | |
| SCHEMBL10105773 | 0.86 | RORC (0.46) | RORCUSP30 | |
| SCHEMBL516800 | 0.86 | MEN1 (0.40) | RBP4BACE1CHRM4CHRM3SMN1; SMN2 | |
| SCHEMBL5723900 | 0.82 | SMN1; SMN2 (0.47) | RORCCHRM4HTTSMN1; SMN2MEN1 | |
| SCHEMBL29051803 | 0.81 | MEN1 (0.36) | RBP4BACE1CHRM4CHRM3USP30 | |
| SCHEMBL29052240 | 0.81 | MEN1 (0.36) | RBP4BACE1CHRM4CHRM3USP30 | |
| SCHEMBL29051800 | 0.81 | MEN1 (0.36) | RBP4BACE1CHRM4CHRM3USP30 | |
| SCHEMBL16625300 | 0.80 | PLA2G1B (0.39) | RBP4MEN1KMT2A | |
| SCHEMBL21222671 | 0.79 | BACE1 (0.38) | RBP4BACE1CHRM3CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329797-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-8470811-B2 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | RBP4 4102/4885BACE1 3246/4885RORC 1598/4885 |
| US-20140329797-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | HIF1AN, HIF1A, EGLN3 | RBP4 1402/4885BACE1 3123/4885RORC 618/4885 |
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | HIF1AN, VHL, HIF1A | RBP4 983/4885BACE1 2264/4885RORC 481/4885 |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | VHL, HIF1AN, HIF1A | RBP4 490/4885BACE1 3281/4885RORC 542/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | RBP4 4102/4885BACE1 3246/4885RORC 1598/4885 |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | HIF1AN, VHL, HIF1A | RBP4 782/4885BACE1 2484/4885RORC 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.